Sensus Healthcare, Inc. (NASDAQ:SRTS – Free Report) – Investment analysts at HC Wainwright lowered their FY2023 EPS estimates for shares of Sensus Healthcare in a research note issued on Monday, November 13th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.14) per share for the year, down from their prior forecast of ($0.09). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2023 earnings at $0.08 EPS, Q1 2024 earnings at ($0.03) EPS, Q3 2024 earnings at ($0.01) EPS and FY2024 earnings at $0.04 EPS.
Separately, TheStreet downgraded shares of Sensus Healthcare from a “c” rating to a “d+” rating in a research note on Friday, November 10th.
Sensus Healthcare Stock Up 1.5 %
Sensus Healthcare stock opened at $2.03 on Wednesday. The company has a market cap of $33.27 million, a PE ratio of -33.83 and a beta of 0.63. Sensus Healthcare has a twelve month low of $1.79 and a twelve month high of $9.62. The company’s 50-day moving average price is $2.47 and its 200-day moving average price is $2.87.
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). The business had revenue of $3.90 million for the quarter, compared to the consensus estimate of $6.04 million. Sensus Healthcare had a negative net margin of 3.58% and a negative return on equity of 1.91%.
Insider Transactions at Sensus Healthcare
In other Sensus Healthcare news, CEO Joseph C. Sardano purchased 10,000 shares of the stock in a transaction dated Thursday, September 14th. The stock was purchased at an average price of $2.88 per share, with a total value of $28,800.00. Following the transaction, the chief executive officer now owns 1,175,293 shares of the company’s stock, valued at $3,384,843.84. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 11.10% of the company’s stock.
Institutional Investors Weigh In On Sensus Healthcare
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in shares of Sensus Healthcare in the first quarter worth $409,000. Dimensional Fund Advisors LP increased its stake in shares of Sensus Healthcare by 92.5% in the first quarter. Dimensional Fund Advisors LP now owns 131,453 shares of the company’s stock worth $1,330,000 after acquiring an additional 63,155 shares during the period. Sei Investments Co. acquired a new stake in shares of Sensus Healthcare in the first quarter worth $216,000. Vanguard Group Inc. increased its stake in shares of Sensus Healthcare by 24.3% in the first quarter. Vanguard Group Inc. now owns 596,224 shares of the company’s stock worth $6,034,000 after acquiring an additional 116,409 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Sensus Healthcare in the first quarter worth $285,000. Hedge funds and other institutional investors own 20.56% of the company’s stock.
About Sensus Healthcare
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
- Five stocks we like better than Sensus Healthcare
- How to Invest in Music Stocks
- 3 value stocks you shouldn’t let go of this quarter
- Stock Splits, Do They Really Impact Investors?
- 5 must-have next-gen technologies that institutions are buying
- How to Invest in Esports
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.